OPEN Foundation

Research

Survey: Quit smoking after a psychedelic experience?

December 6, 2021 / Addiction, Articles, Mystical experiences, Publications, Research / By

Researchers from the Johns Hopkins University School of Medicine are currently recruiting individuals who have quit smoking cigarettes or reduced their smoking (even temporarily) after an experience with a psychedelic, for participation in an online survey. Their team has previously conducted innovative research on the effects of compounds including psilocybin, dextromethorphan, and salvinorin A.

The goal of this survey is to learn more about whether psychedelic drugs are associated with reduction or cessation of cigarette smoking. The researchers want to characterize people’s experiences in non-­laboratory settings in which taking a psychedelic may have led to reducing or quitting smoking. For the purposes of this survey, the survey will be asking specifically about individuals who have quit smoking cigarettes or reduced their smoking (even temporarily) after experiences with psilocybin (magic) mushrooms, LSD, morning glory seeds, mescaline, peyote cactus, San Pedro cactus, DMT, or ayahuasca. This research study has been approved by the Institutional Review Board of Johns Hopkins Medicine.

The survey is completely anonymous (IP addresses will not be recorded) and will require 40-45 minutes to complete. If you are interested in participating, please click this link. Participation is voluntary and will not be financially compensated.

Participants must be 18+ years of age, speak/write English fluently, and have experienced a reduction or cessation of cigarette smoking after an experience with one of the psychedelic substances listed above. For more information, please contact the researchers via the site’s private messaging system.

Principal Investigator of this study, Matthew W. Johnson was a speaker at our Interdisciplinary Conference on Psychedelic Research in 2012. A video on the topic of this study can be watched below.

Psychedelics linked to lower mental health risks

December 6, 2021 / Articles, Background articles, Psychology, Publications, Research / By

The use of LSD, magic mushrooms, or peyote does not increase a person’s risk of developing mental health problems, according to an analysis of information from more than 130,000 randomly chosen people, including 22,000 people who had used psychedelics at least once.

Researcher Teri Krebs and clinical psychologist Pål-Ørjan Johansen, from the Norwegian University of Science and Technology’s (NTNU), cleverly used data from a US national health survey to study the association between psychedelic drug use and mental health problems.

The researchers relied on data from the 2001-2004 National Survey on Drug Use and Health, in which participants were asked about mental health treatment and symptoms of a variety of mental health conditions over the past year. The specific symptoms examined were general psychological distress, anxiety disorders, mood disorders, and psychosis.

The study showed that lifetime use of psilocybin or mescaline and past year use of LSD were associated with lower rates of serious psychological distress. Lifetime use of LSD was also significantly associated with a lower rate of outpatient mental health treatment and psychiatric medicine prescription, although the nature of these relations were not demonstrated in the Norwegians’ study.

Interestingly, the results of this study confirm the outcomes of recent clinical trials that likewise do not demonstrate lasting harmful effects from the use of psychedelics in a clinical setting. It further shows that even when used non-clinically, psychedelic substances might be able to play a role in alleviating mental health issues.

The results are published in the journal PLOS One and are freely available online.

Lecture: Psilocybin in the treatment of end-of-life anxiety

December 6, 2021 / Articles, End of Life Anxiety, Events, Mushrooms / Psilocybin, Publications, Research / By

flashback-psychedelic-research-returns

Dr. Grob will come all the way from Los Angeles to give a lecture on his research into psilocybin, the active ingredient in ‘magic mushrooms’. The main focus of this lecture will be the investigation into the safety and efficacy of psilocybin as a therapeutic aid in the treatment of severe anxiety in adult patients with advanced-stage cancer. Research into substances such as MDMA and ayahuasca, also investigated at the Harbor-UCLA Medical Center, will be addressed as well. There will be ample time for questions and discussion. Students, health care professionals and therapists are encouraged to attend.

Dr. Charles Grob is professor in Psychiatry & Biobehavioral Sciences at UCLA, Los Angeles (USA). He has published extensively on topics such as substance misuse and the history of hallucinogens in psychiatry. He performed the first FDA approved study of the physiological and psychological effects of MDMA; a multi-national study of ayahuasca in Brazil and has performed a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer.
The lecture will take place on Friday 14 June, from 16:00 – 18:00.
LOCATION: CREA (Muziekzaal), Nieuwe Achtergracht 170 Amsterdam.
FEE: €5,- regular / students & alumni get in for free

ICPR 2012 draws attention to psychedelic research

December 6, 2021 / Articles, Events, ICPR 2012 Talks, Publications, Research / By

icpr_church

On October 6 & 7 OPEN’s second international conference took place in Amsterdam: the Interdisciplinary Conference on Psychedelic Research. In a sold out Mozeskerk over 400 researchers, students, therapists and scholars gathered to listen and discuss the latest psychedelic research. From brain imaging studies on psilocybin, philosophical discussions on the meaning of altered states of consciousness to a debate on the place of MDMA in psychotherapy, ICPR set the standard for future events.

Research into psychedelics is slowly being taken seriously in the Netherlands. Dutch science program Labyrint recorded interviews and shot the conference for an episode on psychedelic research. Articles on the conference in Dutch national newspapers Volkskrant (6 Oct. ’12) and Parool (13 Oct. ’12) can be clicked and read here (only in Dutch). Photos of the conference can be found here and videos of the conference are being edited and will be put on our website soon.

Study: no adverse effects in long-time ayahuasca users

December 6, 2021 / Articles, Ayahuasca, Publications, Research / By

An investigation into the psychiatric and neuropsychological status of long-term ayahuasca users – conducted by the Human Experimental Neuropsychopharmacology group of Hospital Sant Pau (Barcelona), in cooperation with IDEAA and research centers in Brazil and Spain – found no evidence of adverse psychiatric or neuropsychological effects. The team performed a longitudinal study of ayahuasca users who had been drinking for at least 15 years, at least twice a month.

The Spanish and Brazilian research team, headed by psychologist José Carlos Bouso, evaluated several domains of mental health in 127 long-time ayahuasca users in religious contexts. They compared these participants with 115 non-users. To confirm the reliability of the results, they repeated the tests one year later. Interestingly, the ayahuasca users showed no personality disorders, and had lower psychopathological indices and better cognitive performance in some neuropsychological tests than the non-users. The study concludes that there is “no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.” These results are consistent with earlier results obtained by other research groups that had studied smaller samples of users. This is the first study with long-term ayahuasca users that both assessed a sample of this size and replicated the results. The authors indicate that the study sample was composed of people that have been using ayahuasca for many years, which is a clear sign that they tolerate the ayahuasca well. The researchers suggest that future studies should focus specifically on participants that initiate the use of ayahuasca and then stop because of a psychological issue possibly related to its use.

José Carlos Bouso is currently a member of the International Center for Ethnobotanical Education, Research & Service (ICEERS) and will be discussing the results of this study during the Interdisciplinary Conference on Psychedelic Research, to be held in Amsterdam on the 6th and 7th of October 2012.

The scientific article (both abstract and full text) can be found here.

Dutch plans for ibogaine research

December 6, 2021 / Articles, Background articles, Dutch, Iboga / Ibogaine, Publications, Research / By

iboga_big

An article in Dutch newspaper de Volkskrant shows there are plans to study the effectiveness of ibogaine in the treatment of addiction in Nijmegen.

The research team, consisting of addiction doctor Maarten Belgers and psychiatrist Toon van Oosteren, works in cooperation with the Radboud University in Nijmegen – to study whether ibogaine can – under strict medical conditions – be used effectively in the treatment of substance dependence. Despite various studies in animals, there has yet been no clinical study in humans. This study would be the first.

In de Volkskrant, Toon van Oosteren states that the researchers intend to subject ten to fifteen people with substance dependence to a treatment with ibogaine. Presently, the team is looking for ibogaine that is pure enough to comply with the rigorous scientific standards for medicines.

Read the whole article in Dutch here.

LSD effective in the treatment of alcohol addiction

December 6, 2021 / Addiction, Articles, Background articles, LSD, Publications, Research / By

alcoholismLSD can be effective in the treatment of alcoholism, according to a new study of a Norwegian research team. This study, published in the Journal of Psychopharmacology, shows that administration of LSD in alcoholics can contribute to the success of the treatment.

In this meta-analysis, the results of six randomized clinical trials that were published between 1966 and 1970 were used. In these studies LSD was administered in a total of 325 cases, and a placebo in 211 cases. Of the patients that received LSD 59% percent improved during the treatment, compared to only 38% of the persons receiving a placebo. The researchers conclude that there is evidence for a positive effect of LSD in the treatment of alcoholism.

Psychedelic research in popular literature

December 6, 2021 / Articles, Background articles, Other, Publications, Research / By

Kijk2The Dutch KIJK magazine printed an article on research on psychedelics. “Tripping away your problems: a slow revival of drugs as medicine”. Reporter Jop de Vrieze interviewed scientists among whom psychiatrists Andrew Feldmár en Charles Grob. Upon the interviews he based that nowadays psychedelics are a “full grown part of scientific studies”. XTC is therapeutically used for emotional illnesses, psilocybine and LSD with treating life quality in terminal illnesses, ketamine is effective with depression and ibogaine with addictions. These positive effects have been known to scientists for decades, yet only recently has public research slowly been allowed again. Both Multidisciplinary Association for Psychedelic Studies (MAPS) and The OPEN Foundation are brought forth in the article as promoting these studies.

The first part of the article (in Dutch) can be read here.

Ayahuasca scientific literature overview

December 6, 2021 / Articles, Ayahuasca, Background articles, Publications, Research / By

iceers3

In response to claims made in 2010 by the United Nations International Narcotics Control Board (INCB) regarding the serious health risks that would entail the use of ayahuasca, psychologist and ayahusaca researcher Jose Carlos Bouso has compiled a document with all the scientific studies into the short, medium and long term effects of ayahuasca. No study supports the claims of the INCB, and some of these studies even indicate a possible therapeutic potential of ayahuasca.

The document was published by the International Center for Ethnobotanical Education, Research and Service (ICEERS), and can be downloaded here.

An honest look at the risks and benefits of MDMA

December 6, 2021 / Articles, Background articles, MDMA, Publications, Research, Safety / By

omag2

Addiction, one of the most important peer-reviewed journals on drug use and abuse, has published the results of a study regarding the use of recreational ecstacy use and potential cognitive damage – which turned out to be absent. The study is unique in that it compared ecstacy users with minimal to no other drug use and non-drug users from the same dance scene.

For years it has been assumed that cognitive skills such as learning and memory would be damaged by heavy ecstacy use. But previous studies always used subjects that also used other drugs, so it could not be determined whether the damage was due to ecstacy use or use of other drugs. This study offers a new light on the matter.

The same day, O Magazine published an article on MAPS’ study of the use of MDMA in psychotherapy for people suffering from PTSD. Sarah, who has suffered from PTSD for twenty years, tells the reader about her experiences with MDMA-assisted psychotherapy for PTSD. You can read the full article here.

30 April - Q&A with Rick Strassman

REGISTER NOW!
X